The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Thursday announced positive data from INSIGHT-003 Phase I trial, evaluating the addition of Eftilagimod alpha or ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

Immutep (IMMP) announces positive data from investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA and chemotherapy for first-line treatment ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...

Immutep (IMMP) stock climbed 11% Thursday after the company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. Read more here.

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.